Transthyretin Amyloid Cardiomyopathy research hub
3 indexed studies · 1 currently recruiting
- recruitingPHASE4
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
This study looks at changing from one heart medicine, tafamidis, to another, acoramidis, for a condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Researchers want to see if switching to acoramidis increases levels of a special protein in your blood even more.
Austria · Belgium · Germany - active not recruitingPHASE3
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
This study is testing a new medicine, ALXN2220, for a heart condition called ATTR-CM. It aims to see if ALXN2220 can help prevent serious heart problems and reduce the risk of death compared to a dummy treatment. We hope to find a new way to help people with this condition.
United States · Argentina · Australia - authorisedTherapeutic use (Phase IV)
i-Care; Quantitative-imaging in cardiac transthyretin amyloidosis
This study, called i-Care, looks at a heart condition called Transthyretin amyloid cardiomyopathy. It uses special scans to better understand how this condition affects the heart. Researchers hope to learn more about tiny calcium deposits and nerve function in the heart, which could help improve future treatments.
Netherlands